Format

Send to

Choose Destination
Crit Care Clin. 2010 Jul;26(3):515-25, ix-x. doi: 10.1016/j.ccc.2010.04.006.

Glutamine in critical illness: the time has come, the time is now.

Author information

1
Department of Anesthesiology, Translational Pharmaconutrition (TPN) Research Laboratories, University of Colorado Denver, Research Complex 2, Box 8602, 12700 East 19th Avenue, Aurora, CO 80045, USA. Lindsay.Weitzel@ucdenver.edu

Abstract

Glutamine (GLN) has been shown to be a key pharmaconutrient in the body's response to stress and injury. It exerts its protective effects via multiple mechanisms, including direct protection of cells and tissue from injury, attenuation inflammation, and preservation of metabolic function. Data support GLN as an ideal pharmacologic intervention to prevent or treat multiple organ dysfunction syndrome after sepsis or other injuries in the intensive care unit population. A large and growing body of clinical data shows that in well-defined critically ill patient groups GLN can be a life-saving intervention.

PMID:
20643304
DOI:
10.1016/j.ccc.2010.04.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center